COMP <GO>
PEN vs ABBV // FORWARD P/E MULTIPLE
Penumbra Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PEN 6
— ABBV 9
▲ FORWARD P/E MULTIPLE LEADER: PEN
LAST: $318.95 (-0.94%) • MKT CAP: $12.68B
forward-pe
60.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PEN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PEN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.10% | 70.20% | -3.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.60% | 29.00% | -18.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 52.0x | 33.3x | +18.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.38% | 3.47% | -2.09 | ABBV | /fcf-yield <GO> |
| Operating Margin | 13.50% | 24.60% | -11.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.70% | 6.90% | +5.80 | PEN | /net-margins <GO> |
| Revenue Growth (YoY) | 17.50% | 8.60% | +8.90 | PEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 21.05 | 5.33 | +15.72 | PEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | PEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.7 | 72.8 | -28.05 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 60.0x | 113.1x | -53.10 | PEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.68B | $513.86B | -$501.18B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PEN REV | ABBV REV | PEN GROSS % | ABBV GROSS % | PEN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $61.16B | 67.1% | 70.2% | $174.9M | $17.82B |
| FY 2024 | $1.19B | $56.33B | 63.2% | 70.0% | $147.3M | $17.83B |
| FY 2023 | $1.06B | $54.32B | 44.0% | 44.0% | $49.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PEN // BETA 0.91
ABBV // BETA 1.15